|
|
|
By Anna Rose Welch, Advancing RNA | Overall, there were two areas of discussion at TIDES that demonstrate the amount of growth we have yet to do as a space — particularly in the realms of regulatory development and quality. As I intend to showcase here in part 1 of this muti-part article, this year’s TIDES was a great reflection of the tension(s) that can arise as we realize how much space exists between where we are and where we’re going next. | |
|
|
|
|
Unlocking The Future Of mRNA | A conversation with BioPhorum members Pamela Hamill and Conor Lake | Many regulatory frameworks and analytical approaches were not originally designed for platforms like mRNA. Addressing these gaps will be essential to fully realize the potential of mRNA technologies. |
|
|
|
|
|
|
|
| From LAL To rFC: The Evolution Of Endotoxin Testing | Application Note | By Thomas Lehman, Ph.D., and Tessa Patton, Eurofins | Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance. |
|
|
|
| 5 IVT Design Considerations Before Scale-Up | Article | Primrose Bio | As RNA programs advance toward clinical manufacturing, five IVT design questions can help teams identify hidden process risks before scale-up exposes them. |
|
|
|
|
|
|
|
.png){kind=logo}
